Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,303 papers from all fields of science
Search
Sign In
Create Free Account
meropenem 1000 MG Injection
Known as:
meropenem 1 GM Injection
, MEROPENEM 1 g in 20 mL INTRAVENOUS INJECTION, POWDER, FOR SOLUTION [Meropenem]
, MEROPENEM 20MG/ML/NACL INJ BAG 50ML
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
24 relations
Anti-Bacterial Agents
Appendicitis
Bacterial Infections
Bacteroides Infections
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Gambaran Efektivitas Biaya Terapi Antibiotik Empiris pada Pasien Sepsis Rawat Inap Penyakit Dalam RSUP Dr. M. Djamil Padang Tahun 2017
K. Khairunnisa
2019
Corpus ID: 202802684
Sepsis adalah disfungsi organ yang mengancam jiwa yang disebabkan oleh respons host yang tidak teregulasi dengan baik terhadap…
Expand
Review
2018
Review
2018
The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria
Michael E. Plazak
,
P. Tamma
,
E. Heil
Expert Opinion on Pharmacotherapy
2018
Corpus ID: 53044150
ABSTRACT Introduction: The rapid spread of Klebsiella pneumoniae Carbapenemase (KPC)-producing bacteria comprises one of the…
Expand
2018
2018
1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β-Lactamase-Producing Enterobacteriaceae in…
Tomefa E. Asempa
,
Ana Motos
,
Kamilia Abdelraouf
,
C. Bissantz
,
C. Zampaloni
,
D. Nicolau
Open Forum Infectious Diseases
2018
Corpus ID: 53836338
Abstract Background NAC is a novel dual action β-lactamase inhibitor with in vitro activity against class A, class C, and some…
Expand
Review
2018
Review
2018
1521. Heterogeneity of Recent Phase 3 cUTI Clinical Trials with New Antibiotics
Almasa Bass
,
R. Echols
,
S. Portsmouth
,
A. Howell
Open Forum Infectious Diseases
2018
Corpus ID: 53798170
Abstract Background For new antibiotics to treat Gram-negative infections, one regulatory pathway includes complicated urinary…
Expand
2018
2018
Diagnostic Microbiology and Infectious Disease
E. López-Camacho
,
J. Paño-Pardo
,
+4 authors
J. Mingorance
2018
Corpus ID: 261934829
⁎ Corresponding author. Tel.: +34-91-2071625. E-mail address: jesus.mingorance@idipaz.es (J. Mingor https://doi.org/10.1016/j…
Expand
2018
2018
HUBUNGAN PEMBERIAN TERAPI ANTIBIOTIK EMPIRIS DENGANLUARAN PADA PASIEN PNEUMONIA RAWAT INAP DI RSUD DRSOETOMO
Putu Dyah Widyaningsih
2018
Corpus ID: 181921734
Latar belakang. Terapi empiris merupakan kunci utama keberhasilan tatalaksana pneumonia. Kegagalan terapi dalam 48-72 jam…
Expand
2017
2017
Potency of Meropenem-Vaborbactam in Lung Surfactant
Debora Rubio-Aparicio
,
J. Loutit
,
M. Dudley
,
O. Lomovskaya
Antimicrobial Agents and Chemotherapy
2017
Corpus ID: 6728015
ABSTRACT This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either…
Expand
2013
2013
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.
A. Teitelbaum
,
Anja Meissner
,
Ryan A. Harding
,
Christopher A Wong
,
C. Aldrich
,
R. Remmel
Bioorganic & Medicinal Chemistry
2013
Corpus ID: 25788871
2012
2012
The distribution according to the species of Gram-negative bacteria isolated from hospitalized patients's urine specimens and their antimicrobial susceptibility
T. Dal
,
A. Tekin
,
+4 authors
S. Dayan
2012
Corpus ID: 56529548
Objective: In this retrospective study, we aimed to determine the distribution according to the species of Gram-negative bacteria…
Expand
2012
2012
Study on decreasing mutant prevention concentrations of imipenemor meropenem in combination with rifampicin against Acinetobacter in vitro
Ma Huimin
,
Hu Lifen
,
Y. Ying
,
Zhu Yu-lin
,
L. Jiabin
2012
Corpus ID: 90745226
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE